To investigate the impact of anti-lymphocyte globulin (ATG-Fresenius) as part of the HLA-sibling transplantation, we evaluated 238 patients (median age 48 years) with different diagnoses (AML, ALL, CML and lymphoproliferative disorders). A total of 79 patients received ATG and 159 patients did not. In the ATG group, there were more HLA-mismatched donors (6% vs 1%, p ¼ 0.02), bad risk patients (70% vs 55%, P ¼ 0.04), reduced intensity conditioning (RIC) regimens (65% vs 34%, P ¼ o0.001) and older patients (median age 51 vs 48 years, P ¼ 0.002). The median time to leukocyte engraftment was significantly faster in the non-ATG group (13 vs 15 days, P o 0.001). EBV reactivation was more often seen in the ATG group (9% vs 2%, P ¼ 0.05). Cumulative incidence of acute and chronic GVHD was less observed in the ATG group (27% vs 40%, P ¼ 0.004, and 33% vs 54%, P ¼ 0.002). The cumulative incidence rates of non-relapse mortality and of relapse at 5 years were 20 and 34%, respectively, for ATG and 34 and 29%, respectively, for non-ATG (P ¼ 0.06 and P ¼ 0.3). ATG can prevent GVHD without an obvious risk of relapse but should be confirmed in a randomized study.
INTRODUCTION
Allogeneic stem cell transplantation from HLA-identical siblings for patients with hematological malignancies has become a curative treatment option. The major cause of treatment failure and death is related directly or indirectly to the occurrence of acute or chronic GVHD. The occurrence of GVHD, especially chronic GVHD, has become more prominent as peripheral blood stem cell transplants are more commonly used for hematopoietic stem cell transplantation. 1 Randomized trials and meta-analyses, however, suggest that using peripheral blood stem cells as graft source is associated with a higher rate of chronic GVHD with substantial impact on the quality of life. [2] [3] [4] [5] [6] Although in unrelated stem cell transplantation the use of ATG within the conditioning regimen has been shown to reduce the risk of acute and chronic GVHD in retrospective as well as in prospective randomized trials [7] [8] [9] [10] the role of ATG in HLA-identical sibling transplantation is less well defined, and smaller retrospective studies suggest similar benefit in reducing acute and chronic GVHD without an obvious increase in relapse as it has been observed in unrelated stem cell transplantation. [11] [12] [13] In a previous study from our own institution, we could show that ATG within the conditioning regimen in HLAidentical sibling transplantation in good-risk leukemia reduces the probability of acute and chronic GVHD without obvious risk of relapse. This study was based on 102 patients who were transplanted between 1999 and 2000 and received mainly bone marrow as stem cell source.
In the current analysis, we focused on transplant period from 2000 to 2011 and selected only those patients who received peripheral blood stem cells as stem cell source.
MATERIALS AND METHODS Patients
This study group comprised 238 patients who received peripheral blood stem cell transplantation from a related donor between 2000 and 2011 at the University Medical Center Hamburg-Eppendorf. A total of 79 patients received ATG-Fresenius (Fresenius Biotech, Gräfelfing, Germany), whereas 159 were conditioned without ATG. The selection for or against ATG was mainly done according to the corresponding clinical trial, which included or excluded ATG within the conditioning regimen. Patient population was diagnosed with AML (39%), ALL (10%), CML (10%), MDS (10%) or lymphoproliferative disorders (31%). The patients were classified as good-risk patients if they presented acute leukemia in first remission (CR1), CML first chronic phase, MDS without blasts or lymphoproliferative disorders in remission at the time of transplant. Thus, overall, 95 patients were classified as good risk and 143 patients were classified as bad risk. The number of bad-risk patients was higher in the ATG group (70 vs 55%, P ¼ 0.04). One percent of the patients in the non-ATG group was HLAmismatched, whereas 6% of the patients in the ATG group were considered to be HLA mismatched. Furthermore, in the ATG group, there were more bad-risk patients, more reduced-intensity conditioning regimens and more elderly patients. Patient characteristics are shown in detail in Table 1 .
Conditioning regimens
A total of 136 patients received a standard myeloablative conditioning consisting mainly of busulfan (14-16 mg/kg body weight) and cyclophosphamide (120 mg/kg body weight) or total body irradiation (12 Gy) and cyclophosphamide (120 mg/kg body weight) or treosulfan (Z 36 g/m 2 ) and cyclophosphamide and etoposide. A total of 105 patients received a reduced-intensity conditioning regimen, which consisted of either busulfan (8 mg) or treosulfan(30 g/m 2 ) in combination with fludarabine (150 mg/m 2 ) or melphalan (140 mg/m 2 ) and fludarabine (150 mg/m 2 ). There were more reduced-intensity conditionings in the ATG arm (65% vs 34%, P ¼ o0.001). Peripheral blood stem cells were infused in general at 24-48 h after the last cyclophosphamide in administration. No manipulation of the graft was performed. The donors were usually mobilized with 10 mg/kg/d G-CSF divided in 2 Â 5 mg/kg/d, and leukapheresis was usually performed in an outpatient setting on day 5 after stimulation with G-CSF and continued on days 6 and 7 if necessary to collect at least 3 Â 10 6
CD34
þ cells/kg of the patient's body weight.
GVHD prophylaxis
GVHD prophylaxis consisted of 3 mg/kg cyclosporine A given from day 1 to 6 months after transplantation. In the reduced-intensity conditioning cyclosporine was tapered after 4 months. The cyclosporine dose was adjusted according to cyclosporine A level (target 200 ng/mL). In addition, patients received either short-course 10 mg/m 2 MTX given on day þ 1, þ 3 and þ 6 after transplantation or 2x1000 mg mycophenolate mofetil given from day þ 1 to day þ 28. A total of 39 patients received ATG with a median dose of 30 mg/kg (r: 20-90 mg/kg) usually divided in three doses given on day 3, 2 and 1. All patients received additional metronidazole (Clont, Bayer, Leverkusen, Germany) at a dose of 400 mg intravenously given three times a day from conditioning until discharge. Standard criteria were used for acute and chronic GVHD.
14 Acute GVHD was treated with high-dose steroids and extensive chronic GVHD with cyclosporine A and steroids.
Supportive care
All patients were nursed in single rooms with HEPA-filtered air. Antibiotic prophylaxis consisted of ciprofloxacin and anti-fungal prophylaxis of fluconazole or posaconazole. Acyclovir was given as herpes prophylaxis from day þ 1 until day þ 180. Pneumocystis carinii prophylaxis consisted of either trimethoprim and sulfamethoxazole for 3-day-a-week or monthly inhalation of pentamidine. All red blood products and platelets were irradiated before infusion, and patients negative for CMV only received blood products from CMV-negative donors. All patients received hematopoietic growth factors (G-CSF 5 mg/kg intravenously) beginning on day þ 5 and continued until the absolute granulocyte count was 4 1.0 /nL for 3 consecutive days. CMV-positive patients were monitored weekly for antigenemia. In case of positive antigenemia, gancyclovir therapy (10 mg/kg daily) or valacyclovir (900 mg) was started. EBV antigenemia was monitored on a weekly basis with the PCR technique.
Statistical analysis
End points were OS, PFS, non-relapse/progressive mortality, incidence of relapse/progress and acute and chronic GVHD. Characteristics of patients were expressed as the median and range for continuous variables and frequencies for categorical variables. Differences in the distributions of the risk factors in two different groups with/without ATG were compared using the chi-square statistic for categorical variables and the Mann-Whitney U-test for continuous variables. The probability of OS and disease-free survival was calculated using the Kaplan-Meier estimator. Death from any cause was an event, and surviving patients were censored at last follow-up. For disease-free survival, the event was defined as death from any cause or relapse/progression. The log-rank test was used to compare survival curves.
In a second step, all variables with a P-value p 0.1 were entered in a multivariable Cox regression model (forward elimination) to determine independent predictors. Only results of the final models are presented as relative risks (hazard ratios) with respect to a reference category (HR ¼ 1) together with the 95% confidence interval (CI) and P-values.
The cumulative incidence method was used to estimate the incidence of non-relapse/progress mortality, relapse and GVHD to account for competing events. For treatment-related death, relapse was the competing event, and, for relapse, treatment-related death was the competing event. The Gray test was used to compare cumulative incidence curves. Calculations were performed with an SPSS, version 19 (SPSS, Chicago/IL, USA), and the competing risk analyses were performed with ACCorD (V. Gebski, NHMRC Clinical Trials Centre University of Sydney).
RESULTS

Engraftment, graft failure and CMV reactivation
No graft failure was observed in the ATG group, whereas one graft failure was seen in the non-ATG group. The median time periods to leukocyte engraftment (41x10 9 /L) were 15 days (r: 10-43) for the ATG group and 13 days (r: 7-30) for the non-ATG group (P ¼ 0.001). Platelet engraftment (4 20 x 10 9 /L) was reached in the ATG group after a median period of 17 days (r: 8-151) and in the non-ATG group after 13 days (r: 8-74) (Po0.001).
The CMV reactivation was only slightly higher in the ATG arm without statistical significance (40% vs 33%, P ¼ 0.4), whereas EBV/ post-transplant lymphoproliferative disease was seen more in the ATG than in the non-ATG arm (9% vs 2%, P ¼ 0.05). However, all patients could be salvaged with rituximab and no patient died due to EBV/post-transplant lymphoproliferative disease (see Table 2 ).
GVHD-and treatment-related mortality Acute GVHD grade II to IV was seen in 40% of the non-ATG group and in 27% of the ATG group (P ¼ 0.4). Severe grade III or IV GVHD was seen in 18% of the non-ATG group and in 10% of the ATG group (P ¼ 0.1). Cumulative incidence rates of chronic GVHD at 1 year were 49% in the non-ATG group and 29% in the ATG group (P ¼ 0.002). Extensive GVHD at 1 year was seen in 39% of the non-ATG and only in 14% in the ATG group (Po0.001). In a univariate analysis for acute GVHD grade II-IV, significant factors for less GVHD were ATG (HR:0.599, P ¼ 0.04) and younger age of the recipient (HR:0.981, P ¼ 0.01). In a multivariate analysis, only myeloablative conditioning remained an independent factor for less acute GVHD (HR:0.416, Po0.001). For chronic GVHD, only the use of ATG-Fresenius was a significant factor for less cGVHD (HR:0.485, P ¼ 0.002). The treatment-related mortality rates at 1 year were 26% in the non-ATG group and 20% in the ATG group. At 5 years, it was 34% in the non-ATG group and remained 20% in the ATG group (P ¼ 0.06) (see Table 2 and Figures 1 and 2) .
Cause of death Major cause of death in both groups was relapse (40%), followed by infection and GVHD. Neither death due to infection (27% vs 33%) nor death due to GVHD (5% vs 19%) was higher in the ATG group.
Relapse, overall and disease-free survival The cumulative incidence rates of relapse were 29% in the non-ATG group and 34% in the ATG group (P ¼ 0.3). In a univariate analysis, the only significant factor for a higher risk of relapse was the use of reduced-intensity conditioning regimen (HR:1.624, P ¼ 0.05). After the median follow-up periods of 57 months (25-80) in the non-ATG group and 63 months (32-110) in the ATG group, the 5-and 9-year progression-free survival rates for the non-ATG group were 37% (95% CI: 29-45) and 26% (95% CI: 12-40), respectively, whereas those for the ATG group were 46% (95% CI: 32-60) and 29 % (95% CI: 11-47), respectively (P ¼ 0.5). The estimated 5-and 9-year overall survival rates for the non-ATG group were 46% (95% CI: 38-54) and 35% (95% CI: 19-51), respectively, whereas the corresponding 5-and 9-year overall survival rates for the ATG group were 54% (95% CI: 42-66) and 38% (95% CI: 20-56) (P ¼ 0.4), respectively (see Table 2 and Figures   3 and 4) . None of the investigated variables (age, donor, conditioning intensity, bad risk, ATG and year of transplantation) were significant for overall survival in a univariate analysis. The only significant factor for an improved overall survival was the diagnosis of both CML and lymphoproliferative disease (P ¼ 0.03). In a multivariate analysis including those factors with a P-value r0.1, risk factors for an improved survival were diagnosis of lymphoid malignancies (HR: 0.429 (95% CI: 0.248-0.742, P ¼ 0.002)) and transplantation in more recent years (HR: 0.648 (95% CI: 0.431-0.975, P ¼ 0.04)), whereas bad-risk disease was associated with poor survival (HR: 1.649 (95% CI: 1.029 ¼ 2.641, P ¼ 0.04)) ( Table 3) .
DISCUSSION
Chronic GVHD is one of the major causes of death after 1 year following allogeneic stem cell transplantation. 3, 15 Although chronic GVHD is associated with a lower risk of relapse, it reduces the quality of life substantially. 5 The incidence of chronic GVHD is more frequent after peripheral blood stem cell than after bone marrow transplantation. [2] [3] [4] 6 As peripheral blood stem cells have become more commonly used as stem cell source, strategies to prevent chronic GVHD without increasing the risk of relapse are needed. 1 ATG has been widely used in HLA-matched and -mismatched unrelated stem cell transplantation in randomized and nonrandomized trials [7] [8] [9] [10] 16, 17 showing a reduction in severe acute GVHD and more strikingly a reduction in chronic GVHD. Our previous experience using ATG-Fresenius as part of the conditioning in the setting of HLA-identical bone marrow transplantation has shown a significant reduction in acute and chronic GVHD without an obvious risk of relapse. 12 Now we investigated the impact of ATG-Fresenius on peripheral blood stem cell transplantation in HLA-identical siblings. Similar to the bone marrow experience, the difference in acute and chronic GVHD was significantly lower in those patients who received ATG 13 The reduction in GVHD by ATG seems to be dose dependent, 9 but prospective studies comparing different doses are lacking so far. More recently, Soiffer et al. described a higher incidence of relapse after in vivo T-cell depletion and dosereduced conditioning; however, here, mainly thymoglobulin and alemtuzumab were used. 18 The other critical issue in using pre-transplant ATG is the kind of ATG preparation. The ATG used in our study is actually an antilymphocyte globulin derived from rabbits after immunization with cells from the Jurkat-T-cell line. The highly purified immunoglobulin consists of antibodies exhibiting a direct effect to T cells via opsonization and lysis following complement activation. As antigens such as CD19, CD138 and others also are targeted by ATG, additional antitumor effect has been demonstrated in B-cell malignancies and, to a lower extent, also in myeloid malignancies. 19 This effect might be the reason for the comparable relapse incidence as one might expect a high risk of relapse by this form of in vivo T-cell depletion. The strong effect of the lower incidence of chronic GVHD is currently unclear. The strong cytotoxic effect of ATG on dendritic cells and B cells 20 may contribute to the reduction in chronic GVHD. Another potential ATG for HLA-identical or -mismatched sibling transplantation C Wolschke et al effect is the induction of regulatory T cells. 21 We did not observe a higher risk of infection-related death in the ATG group, and there was only a trend for a higher CMV reactivation in the ATG group. However, we observed a higher EBV reactivation in the ATG group. Immune reconstitution has not been investigated in this study, but, in previous work, we have shown a significant delay in T-cell reconstitution after ATG-containing conditioning. 22 Pharmacokinetic studies of ATG-Fresenius using ELISA techniques and an inhibitory effect on phytohemagglutinin-induced blastogenesis showed a dose-dependent effect of ATG. Rabbit IgG was detectable over 4 weeks after administration in the recipient after bone marrow transplantation, and the inhibitory effect on phytohemagglutinin response on normal mononuclear cells lasted for 4 days post transplantation. 23 Despite its retrospective character, this study further supports that ATG is reducing the risk of relapse. An ongoing multicenter randomized trial comparing ATG with no ATG in good-risk leukemia patients after HLA-identical sibling transplantation will give more insight into the role of ATG in sibling transplantation. (NCT 00678275) 
